Your session is about to expire
← Back to Search
NIR-ICG Imaging for Rheumatoid Arthritis
Study Summary
This trial is examining the progression of RA and the effectiveness of clinical interventions using NIR-ICG imaging, which is a reliable and reproducible method.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have early RA, didn't respond well to MTX, or it flared up, and I'm starting anti-TNF therapy.I have been diagnosed with rheumatoid arthritis and my disease activity is high.I have early-stage rheumatoid arthritis with a DAS28-CRP score over 3.5.I have been on a stable dose of RA medication for 8 weeks.I have active hand arthritis confirmed by an ultrasound.I am 18 years old or older with early rheumatoid arthritis.I do not have chronic infections like hepatitis B, C, or HIV that could affect the study.I have active inflammation in my hand(s) confirmed by ultrasound.My rheumatoid arthritis was diagnosed within the last year.I have had rheumatoid arthritis for at least 10 years.I am 18 or older with diagnosed rheumatoid arthritis.
- Group 1: Early RA (<1 year of disease)
- Group 2: Established RA (> 10 years of disease)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is the research team engaging in patient recruitment for this trial?
"According to the information on clinicaltrials.gov, this experiment is currently not recruiting participants. It was first posted on December 30th 2021 and modified most recently January 20th 2022. Despite no open recruitment for this study at present, there are 379 other trials actively enrolling patients at this time."
Has the MultiSpectral Imaging System earned regulatory approval by the FDA?
"In accordance with the data provided from our organisation, Power, the MultiSpectral Imaging System is estimated to be of a low level safety rating (1), given that this study is in its first phase and there are limited clinical trials demonstrating efficacy."
Share this study with friends
Copy Link
Messenger